

REGULATORY CONSIDERATIONS FOR THE REGISTRATION OF AVIAN INFLUENZA VACCINES, INCLUDING EMERGENCY AUTHORIZATIONS



AGRICULTURA
SECRETARÍA DE AGRICULTURA Y DESARROLLO RURAL



SENASICA
SERVICIO NACIONAL DE SANIDAD,
INOCUIDAD Y CALIDAD AGROALIMENTARIA



2023
AÑO DE
**Francisco
VILA**
EL REVOLUCIONARIO DEL PUEBLO

REGISTRATION DOSSIER SENASICA PROCEDURE 01-024

Registration
Card *format*

Certificate of origin
If national, the
vaccine strain is
provided by
Senasica.

Master seed
and production
characteristics
If national, it is
provided by
Senasica.

Label and
packaging text
project

Immunizing agent
used

Analytical Report

Biological
control test
results

Sterility test
methodology

Product
Specifications

Analytical
technique

Batch quality
control test
procedures, results
and interpretation
of results

Warnings,
toxicity and
antidote

Primary and
secondary
packaging
description

Manufacturing
protocol

Test: Sterility,
Purity, Strength
and
Immunogenicity,
safety or
innocuousness.

Uses, doses,
routes of
administration

Field tests in
case of imported
product

*Documents that comprise the file
(Art. 153, 154, 155 section V and 156 of
the RLFSA).



Support the
maintenance of master
seed for marketing to
establishments
interested in its
registration **H5N2**



REGISTRATION OF PRODUCTS AT SADER SENASICA PROCEDURE 01-024

AGREEMENT by which the exotic and endemic animal diseases and pests of compulsory notification in the United Mexican States are listed (11/29/2018 DOF).

AGREEMENT by which the campaign and the animal health measures that must be applied for the diagnosis, prevention, control and eradication of Notifiable Avian Influenza are made known, in the areas of the territory of the United Mexican States in which this disease is present . (06/21/2011 DOF)

Guide for the preparation of documents for the registration of biological products for use in animals.

<https://www.gob.mx/senasica/documentos/guias-regulacion-de-productos-veterinarios>



Reception of SENASICA Dossier
*National or imported product



Information analysis
*If necessary, additional information is requested from the owner



Preliminary results are obtained from the official laboratory.



Compliance



Approval Registration No.
B-0000-000



EMERGING VACCINE ASSESSMENT AND SELECTION

- **Invitation to the Pharmaceutical Industry** that produces regulated vaccines for its application in Mexico against AI type A, to present their proposals
- **The sequences obtained from the H5N1 strain corresponding to case CPA-19638-22 are sent** to the laboratories, which are available in the database of the National Center For Biotechnology Information (NCBI):
OP691321.1 ; OP691322.1 ; OP691323.1 ; OP691324.1 ; OP691325.1 ;
OP691327.1 ; OP691328.1
- **Questionnaire request** to know the production capacity and characteristics of the proposed vaccine


EMERGING VACCINE ASSESSMENT AND SELECTION

Questionnaire:

- What genetically engineered vaccines do you produce against Avian Influenza?

Indicate, if applicable, the challenge tests and against which strains of VIAAP the biological produced by you has been submitted. Cite the relevant references

- What is the current production capacity of your company for the mentioned biologics?
- Do you have current records from SADER or another government of the vaccine(s) mentioned? Provide the name(s) of the registered vaccine and its registration number.
- Do you have antigens and antisera for the vaccine(s) you produce?
- Do you market to other countries vaccine(s) against AI, produced in Mexico? (But)
- What vaccination schedule do you recommend for the vaccine(s) you produce?



EMERGING VACCINE ASSESSMENT AND SELECTION

Selection:

- **Documentary review** of the information sent by the laboratories, which was evaluated by technical experts from Senasica.
- **Selection of emergency vaccines** taking into account risk, information from references of studies against the H5N1 strain in other countries.



EMERGING VACCINE ASSESSMENT AND SELECTION

Selection:

3 Vaccines regulated in Mexico are authorized

- Registration No. B-0171-003.
Made in Mexico, currently registered for export purposes only.
Inactivated vaccine derived from genetic engineering.
- Registration No. B-0258-131.
Currently registered for export purposes only.
It is an inactivated vaccine derived from genetic engineering.
- Registration No. B-7378-113.
Registered for sale in Mexico Genetically active virus



Vaccination:

- According to the vaccination protocol established in the **National Animal Health Emergency Device "DINESA"**.

EMERGING VACCINE ASSESSMENT AND SELECTION

Selection:

- **Assessment**, verification and challenge tests **are performed** at the official CENASA laboratory.

Physicochemicals	In vitro	In vivo
Physical inspection	Sterility	Security
Vacuum	Identity	Strength
Humidity	Pollutants	Coexistence
Determination of inactivate	Immunogenicity	
pH	Qualification	

- Tests to be included in the quality control certificate

- **Results are obtained** and a **decision is made whether to maintain or suspend approval of the provisional candidate vaccine** for use during the emergency.

EMERGING VACCINE ASSESSMENT AND SELECTION

Vaccines with satisfactory results in the potency tests:

- Registration No. B-0171-003.
- Registration No. B-0258-131.

Which continued with the authorization for the emergency

The authorization as an emergency vaccine for, Registration No. B-7378-113, **was canceled due to unsatisfactory results.**



EMERGENCY AUTHORIZATION

Determining to conclude with the
vaccination by Senasica



Cancellation of Authorization as an
emergency vaccine



2023
AÑO DE
Francisco
VILA

EL REVOLUCIONARIO DEL PUEBLO

THANK YOU!



AGRICULTURA

SECRETARÍA DE AGRICULTURA Y DESARROLLO RURAL



SENASICA

SERVICIO NACIONAL DE SANIDAD,
INOCUIDAD Y CALIDAD AGROALIMENTARIA